Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide
CUKUROVA MEDICAL JOURNAL, cilt.41, sa.4, ss.811-814, 2016 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 41 Sayı: 4
- Basım Tarihi: 2016
- Doi Numarası: 10.17826/cutf.254553
- Dergi Adı: CUKUROVA MEDICAL JOURNAL
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.811-814
- Çukurova Üniversitesi Adresli: Evet
Özet
Ewing sarcoma family of tumor is the second most common bone tumor in children and young adults, after osteosarcoma. Different chemotherapeutic regimens are used in treatment of relapsed/recurrent Ewing sarcoma. Promising results were achieved with combination of irinotecan and temozolomide. Our case was a 13-year-old female with relapsed Ewing sarcoma and after 12 cycles of irinotecan (20 mg/m2/10 days) and temozolomide (100mg/m2/5 days) treatment she had not any complaints, and her radiological lesions remained stable for 66 months. Irinotecan and temozolomide have been used successfully in treatment of relapsed/recurrent Ewing sarcoma, but there is a need for randomized prospective studies with larger patient groups for establishing the efficacy of this treatment protocol.